Abstract
Objectives The risk of serious health consequences of tobacco use is much higher for people living with HIV than for the general population. Nevertheless, HIV-positive individuals smoke cigarettes 2-3 times more often than others. The aim of this study was to evaluate the prevalence of cigarette smoking among HIV-positive patients in Poland.
Design Data comes from the survey conducted among 204 HIV-positive patients in the period from November 2018 to November 2019.
Methods The characteristics in the survey included: sex; age; present and past smoking habits: the number of cigarettes smoked per day, the number of years as a smoker; the influence of HIV diagnosis on the number of cigarettes smoked.
Results Among all patients, 56.4% (55.1% of all male and 64.3% of all female) were current or former smokers. Among the smokers, 25.2% changed their smoking habits after being diagnosed with HIV: 89.7% increased and 10.3% decreased the number of cigarettes smoked.
Conclusion Prevalence of tobacco use among HIV-positive individuals in Poland decreased since 2009, but is still much higher than in the general population. The outcome indicates the need to improve smoking education provided by HIV care professionals. Smoking cessation treatment should become an integral part of HIV care for patients to fully benefit from antiretroviral therapy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by Medical University of Warsaw Bioethics Committee (Zwirki i Wigury 61 02-091 Warsaw, Poland).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.